XML 22 R10.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Intangible Assets and Goodwill | 9 Months Ended
--- | ---
Oct. 01, 2017
Goodwill and Intangible Assets Disclosure [Abstract] |
Intangible Assets and Goodwill | INTANGIBLE ASSETS AND GOODWILL Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2016. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.
(Dollars in Millions) |  | October 1, 2017 |  | January 1, 2017
Intangible assets with definite lives: |  |  |  |
Patents and trademarks — gross |  | $ | 36,342 |  |  | 10,521 |
Less accumulated amortization |  | 6,395 |  |  | 5,076 |
Patents and trademarks — net |  | 29,947 |  |  | 5,445 |
Customer relationships and other intangibles — gross |  | 20,241 |  |  | 17,615 |
Less accumulated amortization |  | 7,297 |  |  | 6,515 |
Customer relationships and other intangibles — net |  | 12,944 |  |  | 11,100 |
Intangible assets with indefinite lives: |  |  |  |
Trademarks |  | 7,093 |  |  | 6,888 |
Purchased in-process research and development |  | 4,585 |  |  | 3,443 |
Total intangible assets with indefinite lives |  | 11,678 |  |  | 10,331 |
Total intangible assets — net |  | $ | 54,569 |  |  | 26,876 |
Goodwill as of October 1, 2017 was allocated by segment of business as follows:
(Dollars in Millions) |  | Consumer |  | Pharm |  | Med Devices |  | Total
Goodwill, net at January 1, 2017 |  | $ | 8,263 |  |  | 2,840 |  |  | 11,702 |  |  | 22,805 |
Goodwill, related to acquisitions* |  | 102 |  |  | 5,757 |  |  | 2,140 |  |  | 7,999 |
Goodwill, related to divestitures |  | (74 | ) |  | — |  |  | — |  |  | (74 | )
Currency translation/Other |  | 557 |  |  | 89 |  |  | (68 | ) | (1) | 578 |
Goodwill, net at October 1, 2017 |  | $ | 8,848 |  |  | 8,686 |  |  | 13,774 |  |  | 31,308 |
(1) Net of $106 million classified as held for sale, reported in other assets on the Consolidated Balance Sheet, related to the divestiture of the Codman Neurosurgery business which was pending as of October 1, 2017. * Includes measurement period adjustments The weighted average amortization periods for patents and trademarks and customer relationships and other intangible assets are 12 years and 23 years, respectively. The amortization expense of amortizable intangible assets included in cost of products sold was $1,886 million and $895 million for the fiscal nine months ended October 1, 2017 and October 2, 2016, respectively. The estimated amortization expense for the five succeeding years approximates $4.3 billion, before tax, per year. Intangible asset write-downs are included in Other (income) expense, net. The primary driver of the increase to intangible assets and goodwill is related to the Actelion acquisition in the fiscal second quarter of 2017, which resulted in the recording of $25.0 billion to intangible assets and approximately $5.8 billion to goodwill. Additionally, the Abbott Medical Optics (AMO) acquisition in the fiscal first quarter of 2017, resulted in the recording of $2.3 billion to intangible assets and $1.8 billion to goodwill. The intangible assets and goodwill amounts related to the Actelion and AMO acquisitions are based on the preliminary purchase price allocation. See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration